



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/44, 9/54, 9/30		A1	(11) International Publication Number: WO 98/52564 (43) International Publication Date: 26 November 1998 (26.11.98)
(21) International Application Number: PCT/GB98/01465			(74) Agents: WAIN, Christopher, Paul et al.; A.A. Thornton & Co., Northumberland House, 303-306 High Holborn, London WC1V 7LE (GB).
(22) International Filing Date: 21 May 1998 (21.05.98)			
(30) Priority Data: 9710800.5 23 May 1997 (23.05.97)		GB	(81) Designated States: AU, CA, GB, MW, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(71) Applicant (for AT AU BE CA CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE only): CIPLA LIMITED [IN/IN]; Bombay Central, Bombay 400 008 (IN).			
(71) Applicant (for MW only): WAIN, Christopher, Paul [GB/GB]; A.A. Thornton & Co., Northumberland House, 303-306 High Holborn, London WC1V 7LE (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): HAMIED, Yusuf, Khwaja [IN/IN]; Windsor Villa, 2nd floor, Westfield Estate, Off. Bhulabhai Desai Road, Mumbai 400 026 (IN). NAYAK, Vinay, G. [IN/IN]; B38, Suryakiran Society, Senapati Bapat Road, Mahim, Mumbai 400 016 (IN). MALHOTRA, Geena [IN/IN]; 8 Anderson House, Opp. Mazgaon Dock P.O., Mazgaon, Mumbai 400 010 (IN).			

(54) Title: BENZIMIDAZOLE PHARMACEUTICAL COMPOSITION AND PROCESS OF PREPARATION

(57) Abstract

A pharmaceutical composition which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

BENZIMIDAZOLE PHARMACEUTICAL COMPOSITION AND PROCESS OF PREPARATION

The present invention relates to a pharmaceutical composition and to a process of preparation thereof, and more particularly to a pharmaceutical composition containing a benzimidazole.

Benzimidazole derivatives, such as omeprazole, lansoprazole and timoprazole, etc., are known potent proton pump inhibitors with powerful inhibitory action against the secretion of gastric acid (Lancet, Nov. 27, 1982, pages 1223 - 1224). They are used in the treatment of Zollinger-Ellison syndrome and stress related oesophagitis ulceration. The derivatives are well known and are described, for example, in EP-A-0005129.

It has been found that these benzimidazole derivatives, and in particular omeprazole, are susceptible to degradation in acid and neutral media and it is known to protect oral dosage forms by provision of an enteric coating. In this way, the active material is protected from acidic gastric juices until it reaches the site of desired release, e.g. the small intestine. Because certain enteric coatings can themselves be, or contain, acidic materials it is also often required to protect the benzimidazole from the acidity of the enteric coatings. For example, it is known to formulate the benzimidazole with an alkaline material before applying the enteric coating; it is also known to provide an intermediate coating between the benzimidazole and the enteric coating, generally the intermediate coating is selected so as to be substantially water soluble.

- 2 -

EP-A-0247983 describes an oral pharmaceutical preparation of omeprazole which is composed of a core material in the form of small beads or tablets containing omeprazole together with an alkaline reacting compound, the core material having one or more inert reacting subcoating layers thereon. The alkaline reacting compounds can be chosen among but are not restricted to substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; substances normally used in antacid preparations such as aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances, such as $\text{Al}_2\text{O}_3 \cdot 6\text{MgO} \cdot \text{CO}_2 \cdot 12\text{H}_2\text{O}$, $(\text{Mg}_6\text{Al}_2(\text{OH})_{16}\text{CO}_3 \cdot 4\text{H}_2\text{O})$, $\text{MgO} \cdot \text{Al}_2\text{O}_3 \cdot 2\text{SiO}_2 \cdot n\text{H}_2\text{O}$ or similar compounds; organic pH-buffering substances such as trihydroxymethylaminomethane or other similar, pharmaceutically acceptable pH-buffering substances. The specification further states that if an alkaline reacting salt of omeprazole such as the sodium, potassium, magnesium, calcium or ammonium salt of omeprazole (which are described in EP-A-0124495) is used, this can be in place of or in addition to the alkaline reacting compound.

TW289733 describes a process of preparing pellets containing omeprazole. The process comprises spraying a solution comprising omeprazole, excipient, ethanol, water, ammonia and binder on an inert core; granulating; spraying an intermediate coating solution comprising excipient, ethanol, water, ammonia and binder on the granules; and providing a final outer coating.

US4786505 describes pharmaceutical preparations containing omeprazole in an alkali environment as the core material, one or more inert subcoating layers which are water soluble and an outer enteric coating.

There is however provided by the present invention pharmaceutical compositions, and processes of preparing the same, wherein an active ingredient comprising a benzimidazole can be protected from surrounding acidic media, and the compositions offer further advantages over the prior art by exhibiting extended shelf life.

- 3 -

According to the present invention, there is provided a pharmaceutical composition which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating.

There is further provided by the present invention a process of preparing a composition substantially as described above, which process comprises providing an inert core having a benzimidazole therein or thereon, applying a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and applying an enteric coating around the moisture resistant coating.

Preferably, the benzimidazole in or on the core is present in an alkaline environment, and more particularly the benzimidazole is present as an intimate mixture with at least one alkali. Suitably, the alkali is ammonia or a solution of ammonia or ammonium carbonate. A process according to the present invention therefore preferably further comprises formulating the benzimidazole in an alkaline environment substantially as herein described.

It is generally preferred that an alkali employed in the present invention comprises an aqueous solution of ammonia (i.e. ammonium hydroxide) or ammonium carbonate, although it is of course also possible to use liquid ammonia or ammonia gas. In such cases, the benzimidazole may be formulated under an ammonia atmosphere, for example, and the gas may be absorbed, such as by dissolution in any aqueous material present.

In accordance with the invention, the pH of the benzimidazole-containing part of any formulation is preferably from above 7 to 10, and is more preferably in the range 8 to 9. Advantageously, an ammonia solution is used, the solution preferably containing from 20 to 40wt% ammonia, more preferably about 30 wt% ammonia.

The invention is applicable to pharmaceutically active benzimidazole derivatives. Particularly useful such derivatives are the alkali metal salts of the benzimidazole. Examples of specific useful derivatives are omeprazole, lansoprazole, timoprazole, pariprazole and pantoprazole, in particular omeprazole.

The purpose of the moisture resistant coating employed in the present invention is to resist moisture absorption by the pharmaceutical composition, thereby extending shelf life. Suitably, the hydrophobic material of the coating is present in sufficient amount to ensure that the coating substantially repels water therefrom. The hydrophobic material can be solid or liquid, and is desirably selected from the group consisting of a polyalkylsiloxane, castor oil, mineral oil, isopropyl myristate, stearic acid, cetyl alcohol or the like. Preferably, the hydrophobic material comprises a polyalkylsiloxane, and it is particularly preferred that the hydrophobic material comprises polydimethylsiloxane.

The moisture resistant coating may further comprise at least one binding agent. The binding agent may be hydrophobic or hydrophilic. In the latter case, the binding agent is incorporated in the moisture resistant coating in an amount which ensures that the water repellent properties of the latter (as provided by the hydrophobic material substantially as described above), are substantially unaffected by the hydrophilic nature of the binding agent. The binding agent is preferably selected from the group consisting of a sugar, polyvinyl-pyrrolidone, shellac and gums, such as xanthan gum, or the like. It is especially preferred that the binding agent comprises a sugar, such as sucrose or the like.

Advantageously, a binding agent is employed in the moisture resistant coating when the hydrophobic material is a liquid. A preferred moisture resistant coating comprises an emulsion of a polyalkylsiloxane (especially polydimethylsiloxane) or an admixture thereof, with the binding agent.

- 5 -

The moisture resistant coating may contain one or more other conventional additives that typically aid in the process of adhesion onto the inert core.

The moisture resistant coating may also be useful in benzimidazole pharmaceutical compositions that do not have an alkaline binder. The moisture resistant coating can be typically applied by spraying, using conventional equipment. In addition to the moisture resistant coating applied directly to the inert core substantially as hereinbefore described, a further moisture resistant coating can be provided over the enteric coating.

A wide variety of conventional enteric coatings may be employed in the present invention, including for example: cellulose acetate phthalate; hydroxypropyl methyl cellulose phthalate (HPMCP); hydroxypropyl cellulose acetyl succinate; polyvinyl acetate phthalate; copolymerised methacrylic acid/methacrylic acid methyl esters, such as Eudragit L 12-5, Eudragit L 100 55 or Eudragit S 100; and mixtures thereof. The enteric coating may contain conventional plasticisers, pigments and/or dispersants, including for example polyethylene glycols, triacetin, triethyl citrate, and Citroflex, dibutyl sebacate.

The enteric coating can be applied in any suitable manner, for example in the form of an aqueous dispersion in water, or other dispersing medium, or in the form of a solution. It is preferred that a dispersion or solution of the enteric coating is treated with an alkali in order to neutralise at least part of any free acid content. The alkali may be, for example, a carbonate or hydroxide of sodium, potassium, magnesium or calcium.

According to a first embodiment of the present invention, the benzimidazole is present in the inert core. Suitably, the inert core of the pharmaceutical composition comprises a plurality of compressed granules of the benzimidazole. This embodiment is particularly useful when it is desired to provide the pharmaceutical composition in tablet form, and there is further provided by the present invention a tablet which comprises a pharmaceutical

composition substantially as herein described, wherein the inert core is formed from a plurality of granules comprising the benzimidazole, which granules are compressed together to form the core.

According to the first embodiment of the present invention, the moisture resistant coating is applied around the inert core, then the enteric coating is suitably provided around the moisture resistant coating on the inert core.

According to a second embodiment of the present invention, the benzimidazole is present on the inert core. The second embodiment of the present invention is particularly applicable for the inclusion of a plurality of pellets substantially as herein before described in a capsule. The inert cores of the pellets may typically be non-pareils, and suitably provided in the form of sugar beads or sugar/starch beads. According to the second embodiment of the present invention there is therefore provided a capsule which comprises a capsule shell containing a plurality of pellets substantially as herein before described.

According to the second embodiment of the present invention, the moisture resistant coating is applied around the inert core of each of the pellets to be provided in a capsule, and the enteric coating is suitably provided around the moisture resistant coating on each of the inert cores.

Pharmaceutical compositions according to the present invention may comprise one or more additives. Examples of particularly useful additives include a solubiliser to aid solubilisation of the pharmaceutically active ingredient, and a lubricant to aid flow of the active ingredient during manufacture. The solubiliser may be, for example, a sugar, which is preferably in pulverised form. An example of a suitable sugar is sucrose. The lubricant may be, for example, starch and/or talcum. It will be appreciated that the pharmaceutical compositions of the invention may contain any one or more other additives conventionally used in the formulation of pharmaceutical compositions.

The pharmaceutical compositions of the invention may be used to treat conditions in the same manner as the prior known benzimidazole

compositions. The pharmaceutical compositions may be formulated for oral, topical, parenteral or rectal administration. Oral administration is preferred.

The pharmaceutical compositions may take the form of, for example, a tablet or peltab (e.g. comprising a plurality of granules comprising a benzimidazole, together with conventional excipients, such as disintegrants and binders, compressed into a tablet) or a capsule (e.g. containing a plurality of individual pellets comprising a benzimidazole disposed within the capsule shell). Furthermore, the pharmaceutical composition may include conventional excipients.

Tablets to be employed in compositions of the invention can be made, for example, by using equipment known as a marumerizer (which is also called a spheronizer). In such cases, core ingredients, including the benzimidazole, can be extruded into the marumerizer, and converted into substantially spherical granules by a high speed rotating disk. Subsequently, the granules may be compressed by conventional means in order to form a solid core, and subsequently coated with a moisture resistant coating and an enteric coating as herein before described.

When, alternatively, the pellets comprise benzimidazole loaded onto a plurality of inert cores suitable for inclusion in a capsule, the benzimidazole can be supplied as a spray, for example. The benzimidazole may be mixed with one or more additives before being loaded on the inert cores. As described above, the additives may include, for example, a solubiliser and/or a lubricant. The inert cores can be loaded with the benzimidazole (together with any additives), and sprayed with a binder, in a centrifugal coating apparatus.

The following Intermediate Examples and Examples illustrate the invention. In each case, the active drug was omeprazole unless indicated otherwise. Whilst sucrose (sugar) is the illustrated binding agent, other binding agents such as polyvinylpyrrolidone, shellac or xanthan gum, may be used instead.

Intermediate Example 1

A plurality of particles containing the active drug were prepared from the following materials:

Non-pareil seeds	95.00 mg
Active drug	20.00 mg
Sucrose	32.00 mg
Corn starch	32.00 mg
Talcum	10.00 mg
HPMC	1.00 mg

	90.00 mg

Water: as required.

Particles were also made of the above materials with the addition of 30% by weight ammonia solution in an amount to provide a pH of 8.0-9.0.

Initially, the active drug, the sucrose, the corn starch and the talcum were blended thoroughly to yield a dusting powder. The non-pareil seeds were loaded into a centrifugal coater and then coated with the dusting powder while spraying the HPMC (hydroxypropyl methyl cellulose) solution, with the ammonia solution when used. This resulted in the production of a plurality of discrete particles containing the active ingredient. The particles so obtained were dried using conventional tray dryers/fluid bed dryers to an outlet temp. of 45°C.

Intermediate Example 2

A plurality of particles containing the active drug were prepared as follows:

Non-pareil seeds	95.00 mg
------------------	----------

- 9 -

Active drug	20.00 mg
Sucrose	32.00 mg
Corn starch	32.00 mg
Talcum	10.00 mg
HPMC	1.00 mg

	190.00 mg

Water: as required.

Particles were also made of the above materials with the addition of 3.00 mg ammonium carbonate.

Initially, the active drug, the sucrose, the corn starch, the ammonium carbonate (when present) and the talcum were blended thoroughly to yield a dusting powder. The non-pareil seeds were loaded into the centrifugal coater and then coated with the dusting powder while spraying the HPMC (hydroxypropyl methyl cellulose) solution. This resulted in the production of a plurality of discrete particles containing the active ingredient. The particles so obtained were dried using conventional tray dryers/fluid bed dryers to an outlet temp. of 45°C.

Intermediate Example 3

A plurality of particles containing the active drug were prepared from the following materials:

Non-pareil seeds	108.00 mg
Active drug	20.00 mg
Sucrose	35.90 mg
Corn starch	21.10 mg
Talcum	2.00 mg

- 10 -

HPC-L Klucel	1.00 mg
	----- 186.00 mg -----

Water: as required.

Particles were also made of the above materials but with the addition of 3.00 mg ammonium carbonate.

Initially, the active drug, the sucrose, the corn starch, the ammonium carbonate (when present) and the talcum were blended thoroughly to yield a dusting powder. The non-pareil seeds were loaded into the centrifugal coater and then coated with the dusting powder while spraying the HPC-L Klucel (hydroxypropyl cellulose) solution. This resulted in the production of a plurality of discrete particles containing the active ingredient. The particles so obtained were dried using conventional tray dryers/fluid bed dryers to an outlet temp. of 45°C.

Intermediate Example 4

A plurality of tablet cores containing an active drug were prepared from the following materials:

Sucrose	80.00 mg
Corn Starch	86.00 mg
Active drug	20.00 mg
Talcum	1.00 mg
Magnesium stearate	1.00 mg
Gelatine	2.00 mg

	190.00 mg

Water: as required

Particles were also made of the above materials but with the addition of 30% by weight solution of ammonia to give a pH of 8.0-9.0.

Initially the active drug was blended with the sucrose and the corn starch in a suitable mixer. The blend containing the active drug was then granulated with a solution of the gelatine binder (with the ammonia when present). The granules were dried using conventional means, then lubricated with the talcum and magnesium stearate. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.

Intermediate Example 5

Employing the same procedure of Intermediate Example 4, tablet cores were also made of the following composition:

Sucrose	45.00 mg
Dicalcium phosphate	75.00 mg
Corn starch	45.00 mg
Active drug	20.00 mg
Talcum	1.00 mg
Magnesium stearate	2.00 mg
Gelatine	2.00 mg

	190.00 mg

Water: as required

- 12 -

Particles were also made of the above materials but with the addition of 30% by weight solution of ammonia to a pH of 8.0-9.0.

Intermediate Example 6

A plurality of tablet cores containing an active drug were prepared from the following materials:

Sucrose	80.00 mg
Corn Starch	86.00 mg
Active drug	20.00 mg
Talcum	1.00 mg
Magnesium stearate	1.00 mg
Gelatine	2.00 mg

	190.00 mg

Water: as required

Particles were also made of the above materials but also including 3.00 mg ammonium carbonate.

Initially the active drug was blended with the sucrose, corn starch and the ammonium carbonate (when present) in a suitable mixer. The blend containing the active drug was then granulated with a solution of the gelatine binder. The granules were dried using conventional means, then lubricated with the talcum and magnesium stearate. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.

Intermediate Example 7

A plurality of tablet cores containing an active drug were prepared from the following materials:

Active drug	20.00 mg
Mannitol	115.50 mg
Polyvinylpyrrolidone K30	4.00 mg
Crospovidone	7.00 mg
Magnesium stearate	3.00 mg
Talcum	1.50 mg
Polyethylene Glycol	2.00 mg
6000	

	153.00 mg

Water: as required

Particles were also made of the above materials but also including 2.00 mg ammonium carbonate.

The active drug was blended with the mannitol, and then granulated with a solution of PVP-K30 containing ammonium carbonate (when present). The granules were dried using conventional means, then lubricated with the talcum, magnesium stearate, PEG 6000 and Crospovidone. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.

Intermediate Example 8

- 14 -

A plurality of tablet cores containing an active drug were prepared from the following materials:

Active drug	20.00 mg
Mannitol	115.50 mg
Polyvinylpyrrolidone K30	4.00 mg
Crospovidone	7.00 mg
Magnesium stearate	3.00 mg
Talcum	1.50 mg
Polyethylene Glycol	2.00 mg
6000	

	153.00 mg

Water: as required

Particles were also made of the above materials but including 30% by weight ammonia solution to a pH of 8.0-9.0.

The active drug was blended with the mannitol. It was then granulated with the ammonia solution (when present). The granules were dried using conventional means, then lubricated with the talcum, magnesium stearate, PEG 6000 and Crospovidone. Finally, the granules were compressed into a suitable shape for a tablet core using conventional compression equipment.

Intermediate Example 9

190.00 mg of the particles of the composition formed in Intermediate Example 1 were treated with 3.00 mg of polydimethylsiloxane, and as much water as necessary. The coating was carried out using a conventional coating pan.

Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 1.

Intermediate Example 10

190.00 mg of the particles of the composition formed in Intermediate Example 1 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives. The coating was carried out using a conventional coating pan. Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 1.

Intermediate Example 11

193.00 mg of the particles of the composition formed in Intermediate Example 2 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives. The coating was carried out using a conventional coating pan. Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 2.

Intermediate Example 12

189.00 mg of the particles of the composition formed in Intermediate Example 3 were treated with 3.00 mg of polydimethylsiloxane, and as much water as necessary. The coating was carried out using a conventional coating pan.

Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 3.

Intermediate Example 13

189.00 mg of the particles of the composition formed in Intermediate Example 3 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives. The coating was carried out using a conventional coating pan. Instead, it could have been carried out using a fluidised bed coater. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 3.

Intermediate Example 14

Intermediate Example 9 was repeated, using an amount of 30% by wt. ammonia solution, in addition to the polydimethylsiloxane. This produced a moisture resistant coating around the particles of the composition of Intermediate Example 1.

Intermediate Example 15

The 190.00 mg particles formed in Intermediate Example 4 were coated with 3.00 mg polydimethylsiloxane to produce a moisture resistant coating around each particle.

Intermediate Example 16

The 190.00 mg particles formed in Intermediate Example 5 were coated with 3.00 mg polydimethylsiloxane to produce a moisture resistant coating around each particle.

Intermediate Example 17

The 190.00 mg particles formed in Intermediate Example 4 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives to produce a moisture resistant coating around each particle.

Intermediate Example 18

The 190.00 mg particles formed in Intermediate Example 5 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose along with other conventional coating additives to produce a moisture resistant coating around each particle.

Intermediate Example 19

The 193.00 mg particles formed in Intermediate Example 6 were coated with 3.00 mg polydimethylsiloxane to produce a moisture resistant coating around each particle.

Intermediate Example 20

The 193.00 mg particles formed in Intermediate Example 6 were also treated with 20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and

15.73 mg sucrose along with other conventional coating additives to produce a moisture resistant coating around each particle.

Intermediate Example 21

The 190.00 mg particles formed in Intermediate Example 4 were coated with polydimethylsiloxane, and an amount of 30% by wt. ammonia solution, to produce a moisture resistant coating around each particle.

Intermediate Example 22

The 190.00 mg particles formed in Intermediate Example 5 were coated with polydimethylsiloxane, and an amount of 30% by wt. ammonia solution, to produce a moisture resistant coating around each particle.

Intermediate Example 23

A plurality of particles containing the active drug were prepared from the following materials:

Non-pareil seeds	108.00 mg
Active drug	20.00 mg
HPMC	10.00 mg
Polyvinylpyrrolidone	4.00 mg
Talcum	2.50 mg
Water	As required

Total	144.50 mg

Initially, the polyvinylpyrrolidone and HPMC were dissolved in water, to obtain a clear solution. To this solution were added the active drug and talcum, in that order, and dispersed well. This drug suspension was sprayed onto the non-pareil seeds using a fluidised bed coater to obtain drug-loaded cores. These cores were then given a moisture resistant coating in the same way as described in Intermediate Example 9 or 10. Also, an addition of 30% by weight ammonia solution can be used as in Intermediate Example 14.

Intermediate Example 24

A plurality of particles containing the active drug were made from the following materials:

Non-pareil seeds	95.00 mg
Active drug	20.00 mg
Sucrose	30.00 mg
Corn Starch	30.00 mg
Talcum	10.00 mg
Polyvinylpyrrolidone	4.00 mg
HPMC	1.00 mg
Water	As required
<hr/>	
Total	190.00 mg
<hr/>	

Particles were also made of the above materials with the addition of 30% by weight solution of ammonia to pH 8.0-9.0.

The procedure used was as in Intermediate Example 1, the PVP being included in the dusting powder.

Intermediate Example 25

A plurality of particles containing the active drug were prepared from the following materials:

Non-pareil seeds	108.00 mg
Active drug	20.00 mg
Sucrose	35.90 mg
Corn Starch	21.10 mg
Talcum	2.00 mg
Polyvinylpyrrolidone	4.00 mg
HPC-L Klucel	1.00 mg
Water	As required
<hr/>	
Total	192.00 mg
<hr/>	

Particles were also made of the above materials with the addition of 30% by weight solution of ammonia to pH 8.0-9.0.

The procedure used was as in Intermediate Example 1, the PVP being included in the dusting powder.

Intermediate Example 26

The compositions obtained in Intermediate Examples 1 - 8 and 23, 24, 25 were treated with 11.00 mg of a mixture comprising of 2.85 mg of an emulsion of polydimethylsiloxane with 9.00 mg of a binding agent as described earlier (Sucrose/Polyvinylpyrrolidone/Shellac/Xanthan Gum), along with 1 mg of talc. The coating was carried out using a fluidised bed coater. Alternately, it could have been carried out using a conventional coating pan. This produced a moisture resistant coating around each composition of the respective examples.

Example 1

In this Example, the particles formed in Intermediate Examples 9 to 14 were provided with an enteric coating to yield compositions according to the present invention. Some were coated with cellulose acetate phthalate, some with HPMCP and some with Eudragit L 100 55. In each case, 500.00 g of the particles were each coated with 55.00 g of the respective enteric coating polymer. The enteric coating polymer was deposited using a conventional coating process.

Example 2

In this Example, the particles formed in Intermediate Examples 15 to 22 were each coated with an enteric coating polymer to yield tablet compositions according to the present invention. Some were coated with cellulose acetate phthalate, some with HPMCP and some with Euragdit L 100 55. In each case, the enteric coating polymer was deposited using a conventional process for coating.

Example 3

500.00 g of the enteric coated particles from Example 1 were coated with 3.00 mg per unit dosage form of a moisture resistant coating of polydimethylsiloxane. The moisture resistant coating was sprayed onto the particles.

Example 4

500.00 g of the enteric coated particles from Example 1 were coated with 20.00 mg of an emulsion containing 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose per unit dosage form to give a moisture resistant coating. The moisture resistant coating was sprayed onto the particles.

Example 5

500.00 g of the enteric coated tablets from Example 2 were each coated with 3.00 mg per unit dosage form of a moisture resistant coating of polydimethylsiloxane. The moisture resistant coating was sprayed onto the tablets.

Example 6

500.00 g of the enteric coated tablets from Example 2 were each coated with 20.00 mg of an emulsion containing 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose per unit dosage form to give a moisture resistant coating. The moisture resistant coating was sprayed onto the tablets.

Example 7

The enteric coated particles of Examples 1 and 2 were respectively employed in the following formulae:

Particles	193.00 mg
Microcrystalline	20.00 mg
Cellulose	
Starch	50.00 mg
Talcum	1.00 mg

Particles	189.00 mg
Microcrystalline	20.00 mg
Cellulose	
Starch	50.00 mg
Talcum	1.00 mg

- 23 -

The particles were intimately mixed with the other ingredients in a suitable mixer. The resultant blend was made into peltabs which were subsequently respectively provided with a moisture resistant and an enteric coating as follows.

Moisture Resistant Coatings

3.00 mg polydimethylsiloxane (optionally with 30% ammonia solution) to produce a moisture resistant coating around each particle; or

20.00 mg of an emulsion of 4.27 mg of polydimethylsiloxane, and 15.73 mg sucrose, along with other conventional coating additives to produce a moisture resistant coating around each particle.

Enteric Coatings

Enteric coatings included cellulose acetate phthalate, HPMCP and Euragdit L 100 55.

It will appreciated that modifications may be made to the invention described above.

CLAIMS:

1. A pharmaceutical composition which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating.
2. A composition according to claim 1, wherein the benzimidazole is omeprazole, lansoprazole, timoprazole, pariprazole or pantoprazole.
3. A composition according to claim 2, wherein the benzimidazole is omeprazole.
4. A composition according to any of claims 1 to 3, wherein the hydrophobic material is selected from the group consisting of a polyalkylsiloxane, castor oil, mineral oil, isopropyl myristate, stearic acid and cetyl alcohol.
5. A composition according to claim 4, wherein the hydrophobic material comprises a polyalkylsiloxane.
6. A composition according to claim 5, wherein the polyalkylsiloxane is polydimethylsiloxane.
7. A pharmaceutical composition which is a solid pellet comprising an inert core, a benzimidazole in or on the core, a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and an enteric coating around the moisture resistant coating, wherein the

benzimidazole is omeprazole, and the moisture resistant coating comprises a polyalkylsiloxane.

8. A composition according to claim 7, wherein the polyalkylsiloxane is polydimethylsiloxane.

9. A composition according to any of claims 1 to 8, wherein the moisture resistant coating further comprises at least one binding agent.

10. A composition according to claim 9, wherein the binding agent is selected from the group consisting of a sugar, polyvinyl-pyrrolidone, shellac and xanthan gum.

11. A composition according to claim 10, wherein the binding agent comprises a sugar.

12. A composition according to any of claims 1 to 11, wherein the benzimidazole in or on the core is in an alkaline environment.

13. A composition according to claim 12, wherein the benzimidazole is present as an intimate mixture with at least one alkali.

14. A composition according to claim 13, wherein the benzimidazole is present as an intimate mixture with ammonia, ammonium hydroxide or ammonium carbonate.

15. A composition according to claim 14, wherein the benzimidazole is present as an intimate mixture with ammonium carbonate.

16. A tablet which comprises a pharmaceutical composition according to any of claims 1 to 15, wherein the inert core is formed from a plurality of granules comprising the benzimidazole, which granules are compressed together to form the core.
17. A capsule which comprises a capsule shell containing a plurality of pellets as provided by a pharmaceutical composition according to any of claims 1 to 15, wherein the benzimidazole is present on the inert core.
18. A process of preparing a composition according to claim 1, which process comprises providing an inert core having a benzimidazole in or on the core, applying a moisture resistant coating around the core, the moisture resistant coating comprising at least one hydrophobic material, and applying an enteric coating around the moisture resistant coating.
19. A process according to claim 18, wherein the benzimidazole is formulated in an alkaline environment.
20. A process according to claim 19, wherein the benzimidazole is formulated in the presence of ammonia, ammonium hydroxide or ammonium carbonate.
21. A process according to claim 20, wherein the benzimidazole is formulated in the presence of ammonium carbonate.
22. A process according to any of claims 18 to 21, wherein the hydrophobic material comprises a polyalkylsiloxane.

23. A process according to claim 22, wherein the polyalkylsiloxane is polydimethylsiloxane.

24. A process according to any of claims 18 to 23, wherein the benzimidazole is omeprazole, lansoprazole, timoprazole, pariprazole or pantoprazole.

25. A process according to claim 24, wherein the benzimidazole is omeprazole.

26. A process of preparing a tablet according to claim 16, which process comprises compressing together a plurality of the granules to form the core, applying the moisture resistant coating to the core and applying the enteric coating to the moisture resistant coating.

27. A process of preparing a capsule according to claim 17, which process comprises providing the benzimidazole on the inert core, applying the moisture resistant coating thereto, applying the enteric coating to the moisture resistant coating, so as to provide a plurality of pellets as provided by a pharmaceutical composition according to claim 1, and enclosing the pellets in a capsule shell.

INTERNATIONAL SEARCH REPORT

national Application No

PCT/GB 98/01465

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/44 A61K9/54 A61K9/30

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 342 522 A (EISAI CO LTD) 23 November 1989 see abstract see page 2, line 14-29 see page 2, line 42-46 see page 3, line 5-29 see example 5 see claims 1-3,5 --- WO 97 12581 A (PHARMA PASS L L C ;SETH PAWAN (US)) 10 April 1997 see abstract see page 5, line 32 - page 6, line 32 see page 10, line 15-36 see page 11, line 37 - page 12, line 6 see examples 12-14 see claims 1,7-10 --- -/-/	1,18,19
X		1-3,18

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 August 1998

Date of mailing of the international search report

03/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

La Gaetana, R

INTERNATIONAL SEARCH REPORT

national Application No

PCT/GB 98/01465

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 008, no. 106 (C-223), 18 May 1984 & JP 59 020219 A (SHINETSU KAGAKU KOGYO KK), 1 February 1984 see abstract ---	1,4,7, 16-18, 26,27
A	EP 0 247 983 A (HAESELL AB) 2 December 1987 cited in the application see abstract see page 4, line 25 - page 5, line 2 see page 6, line 3 - page 7, line 11 see page 8, line 36 - page 9, line 2 see examples see claim 1 -----	1-27

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/01465

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0342522	A 23-11-1989	JP JP JP CA DK ES FI NO US	1290628 A 2037587 C 7068125 B 1336958 A 239189 A 2051919 T 891650 A, B, 178135 B 5035899 A	22-11-1989 28-03-1996 26-07-1995 12-09-1995 19-11-1989 01-07-1994 19-11-1989 23-10-1995 30-07-1991
WO 9712581	A 10-04-1997	FR FR FR AU AU EP EP WO NO	2742050 A 2745181 A 2747573 A 6998796 A 6998896 A 0854718 A 0859612 A 9712580 A 981284 A	13-06-1997 29-08-1997 24-10-1997 28-04-1997 28-04-1997 29-07-1998 26-08-1998 10-04-1997 20-03-1998
EP 0247983	A 02-12-1987	GB SG AR AT AU AU CA CN CY DE DE DE DK EP EP ES ES FI GR GR	2189698 A 154294 G 240250 A 140387 T 601974 B 7191287 A 1292693 A 1020852 B 1810 A 3751860 D 3751860 T 3783394 A 215887 A 0496437 A 0567201 A 2006457 T 2091971 T 871913 A, B 3007434 T 3020734 T	04-11-1987 17-03-1995 30-03-1990 15-08-1996 27-09-1990 05-11-1987 03-12-1991 26-05-1993 20-10-1995 22-08-1996 21-11-1996 18-02-1993 31-10-1987 29-07-1992 27-10-1993 01-01-1994 16-11-1996 31-10-1987 30-07-1993 30-11-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/01465

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0247983 A		HK 52897 A	02-05-1997
		HK 135294 A	09-12-1994
		HR 920854 A	31-10-1994
		IE 61416 B	02-11-1994
		JP 1863556 C	08-08-1994
		JP 62258320 A	10-11-1987
		JP 2740993 B	15-04-1998
		JP 5294831 A	09-11-1993
		LT 1683 A,B	25-07-1995
		LV 10357 A	20-02-1995
		LV 10357 B	20-04-1996
		NO 174239 B	27-12-1993
		PH 25701 A	18-09-1991
		PT 84785 B	29-12-1989
		SI 8710681 A	31-10-1996
		SU 1820837 A	07-06-1993
		RU 2095054 C	10-11-1997
		US 4786505 A	22-11-1988